H3 Biomedicine

Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds

SF3B is a multi-protein complex essential for branch site (BS) recognition and selection during pre-mRNA splicing. Several splicing modulators with… Read More

H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma

Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic… Read More

H3 Biomedicine to Present at 2018 American Association for Cancer Research Annual Meeting

Presentations highlight leadership in RNA splicing, a strategic focus area of the H3 cancer genomics product engine Read More

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse genomic alterations underlying human cancers. At this historic junction… Read More

H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer

Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients… Read More

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences Across 33 Cancer Types

Hotspot mutations in splicing factor genes have been recently reported at high frequency in hematological malignancies, suggesting the importance of… Read More

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Gene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33… Read More